Cargando…
515: Pathways balancing SARS-COV-2 infectivity and disease severity in CF
Autores principales: | Nakano, S., Okuda, K., Edwards, C., Dang, H., Asakura, T., Kato, T., Mikami, Y., Chen, G., Sun, L., Hawkins, P., Gilmore, R., Morton, L., Ribeiro, C., Pickles, R., Randell, S., O’Neal, W., Baric, R., Boucher, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Cystic Fibrosis Society.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518441/ http://dx.doi.org/10.1016/S1569-1993(21)01939-1 |
Ejemplares similares
-
496: Reduced susceptibility of mice with CF-like lung disease to SARS-CoV-2 infection
por: Hawkins, P., et al.
Publicado: (2021) -
485 Chronic sequelae of SARS-CoV-2 in the Scnn1b-Tg mouse model of cystic fibrosis lung disease
por: Hawkins, P., et al.
Publicado: (2022) -
Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease
por: Kato, Takafumi, et al.
Publicado: (2022) -
SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13
por: Morrison, Cameron B., et al.
Publicado: (2022) -
Mining GWAS and eQTL data for CF lung disease modifiers by gene expression imputation
por: Dang, Hong, et al.
Publicado: (2020)